Research reportD-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
References (34)
- et al.
Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response
Neurosci. Lett.
(1995) - et al.
The effects of anticonvulsant compounds on 4-aminopyridine-induced de novo synthesis of neurotransmitter amino acids in rat hippocampus in vitro
Epilepsy Res.
(1995) - et al.
The role of technical, biological and pharmacological factors in the laboraory evaluation of anticonvulsant drugs. IV. Protective indices
Epilepsy Res.
(1991) - et al.
The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seixure models
Epilepsy Res.
(1991) - et al.
The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models
Epilepsy Res.
(1991) - et al.
Characterization of the anticonvulsant properties of F-721
Epilepsy Res.
(1993) - et al.
Anticonvulsant profile of MDL 27,266: an orally active, broad spectrum anticonvulsant agent
Epilepsy Res.
(1992) - et al.
The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro
Epilepsy Res.
(1995) Intractable epilepsy: Introduction
- et al.
Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes of their preparation and pharmaceutical compositions containing them
(1995)
Allgemeine pharmakologische Untersuchungen mit dem Analgetikum Flupirtin
Arzneim.-Forsch./Drug Res.
Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice
Radiat. Res.
A simplified method of evaluating dose-effect experiments
J. Pharmacol. Exp. Ther.
Do we need novel anti-epileptic drugs?
Br. J. Clin. Pract.
Ralitoline: a reevaluation of anticonvulsant profile and determination of ‘active’ plasma concentrations in comparison with prototype antiepileptic drugs in mice
Epilepsia
Antiepileptic effects of a new drug: D-20443
Epilepsia
Anticonvulsant activity of D-20443
Naunyn-Schmiedenberg's Arch. Pharmacol.
Cited by (223)
Removal of KCNQ2 from parvalbumin-expressing interneurons improves anti-seizure efficacy of retigabine
2022, Experimental NeurologyLamotrigine and retigabine increase motor threshold in transcranial magnetic stimulation at the dose required to produce an antiepileptic effect against maximal electroshock-induced seizure in rats
2022, Neuroscience LettersCitation Excerpt :We measured the effect of retigabine on MES-induced seizures in rats to determine the efficacy of a dose of 5 mg/kg on neuronal excitability. As a result, retigabine at 5 mg/kg almost suppressed the incidence of MES-induced seizures in rats, consistent with a previous report that retigabine inhibited MES-induced seizures in rats at approximately 5 mg/kg (ED50; 5.1 mg/kg, i.p.) [34]. Our rat TMS system had sufficient sensitivity to detect the modulation of neuronal excitability by lamotrigine and retigabine, which can predict antiepileptic efficacy in the MES model in rats.
Ligand modulation of KCNQ-encoded (K<inf>V</inf>7) potassium channels in the heart and nervous system
2021, European Journal of PharmacologyCitation Excerpt :As an example, rats with complex partial seizures have been treated with RTG, which dose-dependently increases the threshold current for induction, and decreases the seizure severity, peak duration and total duration (Tober et al., 1996). It has also an agonistic action on GABAA receptors, which are associated with epilepsy disorders (Rostock et al., 1996; Rundfeldt and Netzer, 2000; Tober et al., 1996). RTG has shown interesting pharmacological action in potentiating KV7.2/3 potassium channels.